Sinopharm Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	36,366	48,796	54,313	63,809	55,222	43,529
Short-Term Investments	-	2,758	3,172	3,330	3,199	2,812
Trading Asset Securities	0.12	0.13	0.16	0.55	0.5	11.75
Cash & Short-Term Investments	36,367	51,554	57,486	67,139	58,421	46,353
Cash Growth	-19.82%	-10.32%	-14.38%	14.92%	26.04%	-12.29%
Accounts Receivable	224,235	206,652	201,479	185,790	171,204	172,576
Other Receivables	20,521	4,938	5,248	4,007	3,703	3,698
Receivables	244,756	211,589	206,727	189,797	174,908	176,273
Inventory	66,633	63,341	62,353	60,028	60,926	51,500
Restricted Cash	-	1,354	1,328	1,850	1,488	-
Other Current Assets	8,335	18,957	19,554	18,022	23,665	16,796
Total Current Assets	356,091	346,796	347,448	336,835	319,406	290,922
Property, Plant & Equipment	15,105	18,229	19,632	19,898	19,647	19,408
Long-Term Investments	11,641	11,310	10,894	10,551	9,840	9,184
Goodwill	5,735	5,784	6,252	7,186	7,156	7,199
Other Intangible Assets	3,826	2,249	2,473	2,830	2,941	3,116
Long-Term Accounts Receivable	-	896.7	1,156	793.92	1,123	874.58
Long-Term Deferred Tax Assets	2,948	2,849	2,408	1,964	1,980	1,787
Long-Term Deferred Charges	1,057	142.29	224.01	180.02	74.44	76.61
Other Long-Term Assets	4,431	2,106	2,344	3,158	2,607	2,845
Total Assets	400,835	390,361	392,831	383,395	364,775	335,412
Accounts Payable	150,804	150,248	151,109	146,632	137,085	128,431
Accrued Expenses	1,373	7,547	8,123	8,832	9,571	8,354
Current Portion of Long-Term Debt	-	63,321	62,729	54,730	52,997	55,152
Current Portion of Leases	-	1,499	1,761	1,797	1,636	1,548
Current Income Taxes Payable	1,880	1,412	1,447	1,775	1,703	1,614
Current Unearned Revenue	6,359	5,984	6,829	6,399	10,396	6,086
Other Current Liabilities	25,045	16,714	18,377	21,326	21,574	18,122
Total Current Liabilities	254,708	246,726	250,376	241,491	234,963	219,307
Long-Term Debt	4,041	3,645	8,637	13,834	11,750	8,419
Long-Term Leases	2,467	2,495	3,259	3,421	3,207	3,250
Long-Term Unearned Revenue	383.83	417.32	413.86	448.24	493.85	462.74
Pension & Post-Retirement Benefits	-	364.9	412.88	366.51	380.71	387.7
Long-Term Deferred Tax Liabilities	637.42	565.22	638.75	788.38	936.74	1,023
Other Long-Term Liabilities	2,107	1,988	2,406	2,727	2,975	2,910
Total Liabilities	264,344	256,201	266,144	263,076	254,706	235,758
Common Stock	3,121	3,121	3,121	3,121	3,121	3,121
Additional Paid-In Capital	20,477	24,641	24,641	24,641	24,641	24,641
Retained Earnings	61,889	60,565	55,532	51,197	44,701	38,516
Treasury Stock	-3.84	-3.84	-3.84	-3.84	-3.84	-3.84
Comprehensive Income & Other	37.81	-4,370	-4,407	-4,373	-4,391	-4,388
Total Common Equity	85,520	83,953	78,884	74,582	68,069	61,886
Minority Interest	50,970	50,206	47,804	45,737	42,001	37,768
Shareholders' Equity	136,491	134,160	126,687	120,319	110,069	99,654
Total Liabilities & Equity	400,835	390,361	392,831	383,395	364,775	335,412
Total Debt	75,756	70,960	76,386	73,782	69,590	68,368
Net Cash (Debt)	-39,389	-19,407	-18,900	-6,643	-11,169	-22,016
Net Cash Per Share	-12.58	-6.22	-6.06	-2.13	-3.58	-7.05
Filing Date Shares Outstanding	3,121	3,121	3,121	3,121	3,121	3,121
Total Common Shares Outstanding	3,121	3,121	3,121	3,121	3,121	3,121
Working Capital	101,382	100,070	97,072	95,344	84,443	71,616
Book Value Per Share	27.40	26.90	25.28	23.90	21.81	19.83
Tangible Book Value	75,959	75,921	70,159	64,566	57,972	51,571
Tangible Book Value Per Share	24.34	24.33	22.48	20.69	18.58	16.53
Buildings	-	14,234	13,752	12,997	12,907	12,127
Machinery	-	11,198	10,728	10,099	9,169	8,412
Construction In Progress	-	842.34	739.81	505.47	800.05	718.53